IL-2 mutein (Takeda Pharmaceuticals/Xilio Therapeutics)

N/A

Report date: 2025/06/11 10:53:17

Base Information

Drug NameIL-2 mutein (Takeda Pharmaceuticals/Xilio Therapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionInterleukin-2 receptor subunit gamma modulatorsInterleukin-2 receptor beta chain modulators
TargetsInterleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXilio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesXilio Therapeutics IncTakeda Pharmaceuticals North America Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A